This week Bioasis heard back from the FDA on written questions they had submitted. These questions concern their lead investigational candidate xB3-001 and its development path. The Company’s goal, of course, is to bring this therapeutic into clinical development...
Tailwinds' Take: Positive in that the timeline for development appears to be unchanged post the meeting, so that implies there were no significant issues from the FDA's side. How they fund this going forward remains a mystery to me....
Tailwinds' Take: this is a nice announcement, securing more IP around this platform technology. We remain intrigued by the Company, especially at this valuation, but would like to see a clearer path to financing before stepping up in a...
I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a swoon. This time, thanks to the ratcheting up of trade tension, we looked ready for...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas...
Tailwinds' Take: Obviously, this cash was needed and will not suffice them for long. We would like to see just how much director and management participation took place in this round. The next catalyst is an FDA meeting in...
One of my favorite shows to watch on airplanes used to be The Deadliest Catch. This real life drama portrays a group of Alaskan king crab fisherman as they ply their trade in the Bering Sea. Every year during crab season, these...
Tailwinds' Take: The Company needed this cash infusion rather desperately. I believe that management participated in the transaction. The technology is solid, but they need to develop a long-term plan to fund Bioasis. GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (“Bioasis” or the...
Tailwinds' Take: while this news comes suddenly and will likely cause some selling in the stock, we view it as constructive. Mark Day has never gotten the traction needed with financing and, frankly, our communications with him have been...
Tailwinds' Take: Bioasis appears to have done the necessary pre-clinical work to attract interest from partners. While still early stage, it's apparent that the platform has significant promise and I expect to see more deals in the near future. GUILFORD,...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.